Kazia Therapeutics Ltd. (KZIA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
KZIA Profit Margin, ROE & Profitability Analysis
KZIA vs Healthcare Sector: How Kazia Therapeutics Ltd. Compares
How Kazia Therapeutics Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kazia Therapeutics Ltd. Stock Overvalued? KZIA Valuation Analysis 2026
Based on fundamental analysis, Kazia Therapeutics Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kazia Therapeutics Ltd. Balance Sheet: KZIA Debt, Cash & Liquidity
KZIA Revenue Growth, EPS Growth & YoY Performance
KZIA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kazia Therapeutics Ltd. (CIK: 0001075880)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KZIA
What is the AI rating for KZIA?
Kazia Therapeutics Ltd. (KZIA) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KZIA's key strengths?
Claude: Analysis in progress.
What are the risks of investing in KZIA?
Claude: Analysis in progress.
What is KZIA's revenue and growth?
Kazia Therapeutics Ltd. reported revenue of N/A.
Does KZIA pay dividends?
Kazia Therapeutics Ltd. does not currently pay dividends.
Where can I find KZIA SEC filings?
Official SEC filings for Kazia Therapeutics Ltd. (CIK: 0001075880) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KZIA's EPS?
Kazia Therapeutics Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KZIA's fundamental grade?
Based on our AI fundamental analysis in July 2026, Kazia Therapeutics Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KZIA stock overvalued or undervalued?
Valuation metrics for KZIA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KZIA's AI grade for 2026?
Our dual AI analysis gives Kazia Therapeutics Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KZIA's free cash flow?
Kazia Therapeutics Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does KZIA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).